Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 15.22
Key Takeaways
Risk factor
Meaningful price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Data is available to registered users only
